Table 1.
Characteristics of Patients and Controls
| Patients with AD without DAOSD | Patients with AD and DAOSD | P Value‡ | Controls | |
|---|---|---|---|---|
| Count (%) | 14 (70) | 6 (30) | 10 | |
| Age (yrs, median)∗ | 45 | 37 | 0.74 | 30 |
| Gender: | ||||
| Male (count, %) | 9 (64) | 4 (67) | 5 (50) | |
| Female (count, %) | 5 (36) | 2 (33) | 5 (50) | |
| Male/female (count)† | > 0.99 | |||
| History of ocular surface disease (count, %)† | 6 (43) | 3 (50) | > 0.99 | 0 |
| Topical lubricants at baseline(count, %) | 4 (29%) | 2 (33%) | > 0.99 | 0 |
| Asthma bronchial (count, %)† | 4 (29) | 2 (33) | > 0.99 | 0 |
| Visit 1 - baseline | ||||
| No. of patients (count, %) | 14 (100) | 6 (100) | 10 (100) | |
| EASI (median) | 33.2 | 27.2 | 0.43 | NA |
| IGA (median) | 4 | 4 | 0.58 | NA |
| Visit 2 – 1 mo | ||||
| No. of patients (count, %) | 11 (79) | 5 (83) | NA | |
| EASI (median) | 13.9 | 14.6 | 0.46 | NA |
| IGA (median) | 3 | 3 | 0.91 | NA |
| Visit 3 – 4 mos | ||||
| No. of patients (count, %) | 12 (86) | 6 (100) | NA | |
| EASI (median) | 8.5 | 10.9 | 0.35 | NA |
| IGA (median) | 2 | 3 | 0.91 | NA |
| Visit DAOSD | ||||
| No. of patients (count, %) | NA | 6 (100) | NA | |
| Interval between visit 1 and visit DAOSD (days [median], range) | NA | 53.5 (28–103) | NA | |
| EASI (median) | NA | 11 | NA | |
| IGA (median) | NA | 3 | NA | |
| Conjunctivitis (count, %) | NA | 6 (100) | NA | |
| Keratitis (count, %) | NA | 2 (33) | NA | |
| Blepharitis (count, %) | NA | 6 (100) | NA |
AD = atopic dermatitis; DAOSD = dupilumab–associated ocular surface disease;
EASI = Eczema Area and Severity Index; IGA = Investigator Global Assessment; NA = not applicable.
∗
Wilcoxon rank sum test.
†
Fisher exact test for count data.
‡
P values are shown for comparisons between patients with AD and DAOSD vs. without DAOSD.